BioNTech SE
BNTXSell · Weight Down
ARK net-sold the stock and the price fell, decreasing its portfolio weight.
Shares -99.7% · Market value -99.7% · Weight -0.08%p
| Date | Action | ETF | Shares | Close | Est. total |
|---|---|---|---|---|---|
| 26.07.10 | SELL | ARKG | 307 | $91.49 | $28.1K |
| 26.07.09 | SELL | ARKG | 849 | $92.98 | $78.9K |
| 26.07.08 | SELL | ARKG | 78,211 | $93.53 | $7.3M |
| 26.07.07 | SELL | ARKG | 44,330 | $94.29 | $4.2M |
| 26.03.03 | BUY | ARKG | 122,951 | $100.76 | $12.4M |
Prices estimated from market closing prices on trade dates. Actual execution prices may differ. This is not investment advice.
Based on ARK ETF real-time + 13F quarterly filings
13F data may be delayed up to 90 days.
Analyst Consensus
※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.
Price Information
Trading Volume
Valuation
Financials
Profitability
Dividend
Technical
BioNTech SE is a biotechnology company focused on developing and commercializing innovative immunotherapies for cancer and infectious diseases. The company has a broad pipeline of investigational treatments, including mRNA-based therapies and other novel approaches, targeting various solid tumors and other serious conditions. BioNTech is a significant player in the field of cancer immunotherapy, with a strong emphasis on clinical development and advancing its diverse product candidates.
AI-generated summary. Not investment advice.
Related ARK stocks
Explore companies with similar themes or neighboring ARK trading activity.